

FIG. 1






FIG. 2A

Construction of
pBTM116 (LexA)-(X)15

Library DNAs of
pBTM116 (LexA)-(X)15

Large scale transformation
of yeast L40



His⁺, β -gal⁺

Curing of pVP16-FAP-1

Isolation of
pBTM116 (LexA)-(X)15

Analysis of
DNA sequences

209060 "BET2600T

FIG. 2B

Human	D	S	E	N	S	N	F	R	N	E	I	Q	S	L	V
Rat	S	I	S	N	S	R	N	E	N	E	G	Q	S	L	E
Mouse	S	T	P	D	T	G	N	E	N	E	G	Q	C	L	E

FIG. 2C

- - - N S - - - N E - Q S L -


C	Y	A		A	I	G		L							V	12-0
E	N	A		G	V	S		E							V	5-0
W	W	G		A	T	Q		P							V	13-0
E	H	A		Q	Q	Q		Q							V	20-0
N	S	S		F	H	S		L							V	6-2
G	L	R		L	P	P		D							V	9-5
G	S	D		S	G	V		N							V	18-1
K	K			R	P	V		N							V	22-1
I	G	K		D	V	W		A							V	71-1
A	S	R		N	E	E		L							I	14-5

FIG. 2D

I	P	P	D	S	E	D	G	N	E	E	Q	S	L	V	8-1
D	S	E	M	Y	N	F	R	S	Q	L	A	S	V	V	9-3
I	D	L	A	S	E	F	L	F	L	S	N	S	F	L	14-1
P	P	T	C	S	Q	A	N	S	G	R	I	S	T	L	0-2
S	D	S	N	M	N	M	N	E	L	S	E	V			57-5
Q	N	F	R	T	Y	I	V	S	F	V					72-1
R	E	T	I	E	S	T	V								25-9
R	G	F	I	S	S	L	V								16-13
T	I	Q	S	V	I										6-3
E	S	L	V												18-1


Consensus: t S-X-V/L/I

FIG. 3A



5/28

FIG. 3B



209020" 8ET2600T

10092138" 030602

1

6/28

Inhibition of Fas/AP-1 Binding (%)

SLX


SXV

XLV

A D E F G H I K L M N Q R S T V W Y

7/28


FIG. 4A



2050ED-8ET2600T

8/28

FIG. 4B



2090E0 "BET2600T

FIG. 4C





FIG. 4D



2090E0" 8EF2600F

10/28


FIG. 5B

Ac-SLY-OH

FIG. 5A

Ac-SLV-OH

Phase contrast



2090ED BET2600F


11/28

FIG. 5D

AC-SLY-OH

FIG. 5C

AC-SLV-OH




2090E0 SET2600F

12/28


FIG. 5F
Ac-SLY-OH

FIG. 5E
Ac-SLV-OH



Hoechst 33342

FIG. 6



2090ED "BET2600F

FIG. 7A

NGF Receptor

1 mgagatgram dgprllllll lgvslggake acptglyths gecckacnlg egvaqpcgan
 61 qtvcepclds vtfsdvvsat epckpctecv glqmsapcv eaddavcrca ygyyqdettg
 121 rceacrvicea gsglvfscqd kqntvceecp dgtysdeanh vdpclpctvc edterqlrec
 181 trwadaecee ipgrwitrst ppegdstap stqepeappe qdliastvag vvtvmgssq
 241 pvvtrgttdn lipvycsila avvglvayi afkrwnsckq nkqgansrpv nqtppegeek
 301 lhdsgisvd sqslhdqqph tqtasggalk gdgglysslp pakreevekl lngsagdtwr
 361 hlageelgyqp ehidsfthea cpvrallasw atqdsatlida llaalrriqr adlveslcse
 421 statspv

FIG. 7B

CD4 Receptor

1 mnrgvpfrhl llvlqlallp aatqgkvvl gkkgdtvelt ctasqkksiq fhwnsnqik
 61 ilgnqgsflt kgpsklndra dsrrslwdqg nfpliciiknlk iedsdtyice vedqkeevql
 121 lvfgltansd thllqgqslt ltlesppgss psvqcrsprg kniqggkttls vsqlelqdsq
 181 twtctvlqnq kkvefkidiv vlafqkassi vykkegeqve fsfplafteve kltgsgelww
 241 qaerasssks witfdlknke vsvkrvtqdp klqmgkklpl hltlpqalp qagsgnltla
 301 leaktgklhq evnlvmrat qlqknltecew wgptspklml slklenkeak vskrekavvw
 361 lnpeagmwqc llsdsgqvll esnikvlptw stpvqpmali vlvgvaglll figlgi ffcv
 421 rcrhrrrae rmsqikrlls ekkctqcphr fqktcspi

FIG. 7C

Species	C-terminal sequences of NGFR (p75)	Binding activity of FAP-1
Human	SESTATSPV-COOH	+
Rat	SESTATSPV-COOH	+
Chicken	SESTATSPV-COOH	+

2090ED" SET2600T

FIG. 7D

1 mnsqvmkyg ndsaeelsel hsaalaslkq divolnkrllq qtererdlle kklakaqceq
 61 shlmrehedv qerttlryee ritelhsuia elnkkidrlq gttireedey selrselsqs
 121 qhevnedss mdqdtstsvsi pengstmvtat dmdncsdins elqrvtgle nvvcgrkkss
 181 cslsvaevdr hieqlttase hcdlaiktve eieglgrdl ypnlaeersr wekelagire
 241 enesltamlc skœœlnrtk atnnaireer drlrrrvrel qtrlqsvqat gppsppgrits
 301 tnrplnpstg elstssssnd ipiakiaerv klsktræss sddrplvgse issigvsssv
 361 aehiahsldq csniqelfqt lyshgsaise skirefevet ørlneriehl ksqudlittit
 421 leecksnaer msmlyvgkyœ natairlalq yseqcieaye lllalaeœq slilgcfræa
 481 gvgsepgdqs gdenitqmlk rahdcrktae naakallmkl dgecgafav agcsvqpwoe
 541 lssnshtstt sstasscdte ftkedegrk dyiqqlkndr aavkltmlle øsihidplsy
 601 dvkprgdsqr ldlenavlmq elnamkeena elkaqllylle kekkalelkl streaqeqay
 661 lvhiøhlksø vœeqkeqrmr slsstssgsk dkpgkecada aspalslael rttcsenela
 721 aeftnairre kklkarvqel vsalørltks seirhqqsae fyndlkrans nlvaayekak
 781 kkhgnklkl esqmmamver hetqvrmlkg riallœœns rphntne~~la~~

FIG. 7E

```

1 madvfpngds tasqvanrf arkgalrqkn vhevkdhkfl arfkqptfc shctdfiwgf
61 gkqgfcqvc cfvvhkrche fvtfscpgad kgpdtddprs khkfkhtyg spfcdhcg
121 llyglihqgm kcdtdmnhv lsdpyvklkl ipdpkneskq cgm dhtakrg rylkaevad eklhvtvrda
181 knlipmdpng trndfmgsls fgvselmbmp asgwykllnq eegeyyynvpl pegdeegnme
241 sveiwdwdrt gpagnkvisp kkdvvigddd vectmvekrv lalldkppfl tqlhscfqtv drlyfvmeyv
301 lrqkfekakl teelyaikil nggdlmyhiq qvgkfkepqa vfyaaeisis ayqpygksvd wwaygvllye mlagqppfdg
361 dfgmckehmm dgtvtrtfcg lskavslck glmtkbpakr lgcgpegerd vrehafrri
421 ededelfqsi mehnvsypks kgaenfdkff trggqvltpg dqlvianidq sdfegfsyvn
481 dweklenrei qppfkpkvcg
541 pqfvhpllqa av
601
661

```

FIG. 7F

1 mdilceents lestunslmq inddtrlysn dfnsgaents dafnwtvdso nrtalscegc
 61 lpsclslhh lqeknwsall tavvilltia gnilyimavs lekklqnatn yflmslaiaa
 121 mllgflvmpv smltilygyr wplpsklcav wiyldvlfst asimhlcais ldryvaigmp
 181 ihnsrfsrt kafllkllavw tlgvglsmp lqvglqddsk vfkegscilla ddnfvlisef
 241 vefflpltim vityfltkis lqeatlcvs dlgttraklas fsflpqesls sekfgrsah
 301 repggytgrr tmqsisneqk ackvlgivff lfvmwcpff itriravick escnedviga
 361 invfwigy lssavmplvy tlfnktyrsa fsrylqcqyk enkkplqlil vntipalayk
 421 seqlmggqkx nskqdakttd ndcsmvalgk qhseeaskdn sdgvnekvay

FIG. 7G

1 malsyrvsei qstipehiq stfwhvissn wsglqtesis eemkqiveeq gnklhwaall
 61 ilmvlptig gntlvllavs lekklqyatr yflmelavad llvglfvmpi alltimfoam
 121 wplplvlcpa wlfldvlfst asimhlcais vdryialkkp iqanqynera tafikityvw
 181 llsigialpv plkgietdvd npnnitcvlt kerfgdmlf gslaafctpl aimivtyflt
 241 ihalqkkayl vknppqrilt wltvstvqr detpcsspek vamlgdrkd kalpnsqdet
 301 lmrrtstgk ksvqtieneq raskvlgivf flflmwcpf fitnitvlc dscnqttlqm
 361 lleifwigy vssgvnplvy tlfkktfrda fgryitcnvr atkavktlrk rsakiyfrnp
 421 maenskffkk hgirnginpa myqspmrirs stiqassii idtllltene gdkteeqvay
 481 y

FIG. 7H

1 maaasydqi: kqvealkmen snlrgeledn snhltcklete asnnkevlkq lqgsiedeam
 61 assggidlle rikelnldss nfpvgklrsk msirsygare gsvssrsgec spvpmgsfpr
 121 rgfvngsres tgyleeleka rsllladldk eekekdwyya qlqmltkrid slptanfsi
 181 qtdmtrrqlc yearqirvan eeqlgtcqdm ekraqrriar lqglekdil: irqlqsgat
 241 eaeressqkh eigshdaerq negqgvgein matagngqgs ttrmdnetas vlssssthsa
 301 prrltshlgt kvemyslls mlgtthdkddm srltiamss qdscismrqs gelpiliql
 361 hgnkdksvll gnsrgskear arasaalhui ihsgpddkrg rreirvihl eqiraycctc
 421 wewqeahepg mdqdkmpmpa pvehqicpav cvlnklisfde ehnhamnelg glqaiaelig
 481 vdcemygltn dhysitlrry agmaltnltf gdvankatic smkgcmraiv aqlksesedi
 541 qqviasvlrn lswradvnsk ktlrevgsvk almecalevk kestlksvls alwnlsahc
 601 enkadlcavd galafivgtl tyrsqtnla iiesgggilr nvssliatne dhrqilrenn
 661 clqtllqhlk shsltivsna cgtlwnlsar npkdqealwd mgavsmknl ihshkkmiam
 721 gsaaairnlm anrpakykda ninspgsslp slhvrkqkal eaeldaqhls etfdnidlsl
 781 pkaahrskqr hkqslvgdyv fdtnrhddnr sdafntgnnt vlspylnttv lpsssssrqs
 841 ldsrsekdr slerergigl gnyhpatenp gtskkrqlq sttaaqiakv meevsaihts
 901 qedrsgstt elhcvtderm alrrssaahh hsnntynfks ensnrtcsmp yakleykrss
 961 ndslnavsss dgygkrqgmk psiesysedd eskfcsygyy padlabkihs arhmdnddce
 1021 ldtcpinyslk ysdeqlnsgr qspqnerwa rpkhliledel kqseqrgsm qsttypvyte
 1081 stddkhlkfq phfgqqecvs pyrsrgang etnrvgsnhg inqrvsgslc qeddyeddkp
 1141 tnyseryse eqheeeerpt nysikyneek rhdvdpidys lkyatdipss qkqsfssks
 1201 ssgqsskteh mssssentst pssnakrqmq lhpssaqsrs gqpkaateck vssinquetiq
 1261 tycedvtpic fsrccslasl ssaedeigcn qttqeadsan tlqiaeikek igtrsaedpy
 1321 sevpavsqhp rtkssrlqgs slssesarhk avefssgaks paksgaqtprk sppahyvqet
 1381 plmfarctsv ssldsfesrs lassvqsepc sgmvsgilsp sdipdsppgt mppsrektp
 1441 pppqtaqtcr evpknkaptk ekresgpkqa avnaavqrvg vlpdadtllh fatestpdgf
 1501 scssslsals ldepfiqkdv elrimppvqe ndngmetase qpkcsnenge keaektidse
 1561 kdilddsddd dieileeci samptkssrk akkpaqtask lpppvarkps glpvyklips
 1621 qurlqpqkhv sftpgddmpr vycvegtpin fstatsladi tiesppnela agegvrsgaq
 1681 sgfekrdti ptegrstdea qggktsavti peidmkaee gdilaecins ampkqkshkp
 1741 frvkkimdv qqasasssap nknqldgkkk kdrspvkip qnteyrtrvr knadsknnln
 1801 aervfsdndkd skkqnlknns kdfndklpna edrvrgsfaf dsphhytpie gtpycfsmnd
 1861 slssldfddd dvdlrrekae lrkakenkes eakvtshte: tsnqqsanct qalakkpinr
 1921 gqpkpilqkq stfpqsskdi pdrgaatdek lqnfaietp vcfshnssls slsldidqenn
 1981 nkenepiket eppdsqgeps kpqasgyapk sfhvedtpvc fsmssslssi sidseddllq
 2041 ecissampkk kkpssrlkgdn ekhsprnngg ilgedltldi kdiqrpdseh glspdsenfd
 2101 wkaigegans ivsslhqaaa aacslrqass dsdsilslks gislgspfh: tpdqeekpft
 2161 ankqprilkp gekstletkk iesseskigk gkkvykslit gkvrnsneis gmkqplqan
 2221 mpsisrgtrm ihipgvnss sstspvskkg ppiktpasks psegqtatts prgakpsvks
 2281 elapvarqts qiggsskaps rsgsrdstps rpaqqplsrp lqspgrnsis pgrnglspn
 2341 klsqlprtss petastkssg sgkmsytspg rqsqqnltk qtglsknass iprsesaskg
 2401 lnmnngnga nkkelssrms stkssgsesd rserpvlvrq stfikeapsp tlrrkleesa
 2461 efeslapssr pasptrsqaq tpvlspslpd mslsthsavq aggrwrlppr leptieyndg
 2521 rpakrhdiar shsespsrlp inrsgtwkre hskhssslpr vstwrtrgss ssilsasses
 2581 sekaksedek hvnsisgtkq skenqvsakg twrkikenef spnatsqtv ssgatnzaes
 2641 ktliygmapa vsktedvwr ldedpinnpr sgrsptgnnt pvidsvseka npmikdskdn
 2701 qakqnvngs vpmrtvglen rlnsfqvda pdqkgteikp gqnpvqvse tnessivert
 2761 pssssssskh sspsgtvaar vtpfnynpss rkssadstsa rpsqiptpvn nntkkrdskt
 2821 dstessgtqs pkrhsssyly lxx

FIG. 8

p75NGFR
(Low-affinity nerve growth factor receptor)




FIG. 9

	C-terminal amino acid sequence
Fas	NEIQSLV
p75NGFR	STATSPV




FIG. 10
In vitro interaction of ³⁵S-labeled FAP-1 with various receptors
— FAP-1 binds to the cytoplasmic region of p75NGFR. —




FIG. 11A
FAP-1 binds to C-terminal three amino acids SPV of p75NGFR.




FIG. 11B




FIG. 12

FAP-1 binds to p75NGFR C-terminal cytoplasmic region in yeast.

	VP16-FAP-1	VP16-cRaf
LexA-p75NGFR(338-396)	+	-
LexA-p75NGFR(365-396)	+	-
LexA-Fas	++	-
LexA-Ras ^{V12}	-	+
LexA-Lamin	-	-

FIG. 13A




FIG. 13B





FIG. 13C



10092138.030602

FIG. 14A

Plain-glass slide



FIG. 14B

3D gel pad chip





FIG. 14C

Microwell chip



20090213-030600